CORAL GABLES, FL / ACCESSWIRE / December 3, 2018 / Attention on Healthcare Market has continued to accelerate this quarter. This has been especially true when it comes to the companies within the health tech and med tech segments of the market. The global healthcare IT market is expected to post a CAGR of over 8% during the period 2018-2022, according to the latest market research report by Technavio.
"Improving healthcare services have led to an increase in the average human lifespan. This has led to an increase in chronic diseases, and the number of patients necessitating the need reduce the per-patient time of a doctor and to increase the efficiency of treatment. The healthcare IT solution will play a significant role in automating the treatment process right from the admission of patients, to maintaining records of treatment and scheduling follow-ups," says a senior analyst at Technavio for research on IT professional services.
Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI)'s subsidiary, HealthVue is focused on developing proprietary technology to deliver quality healthcare through the combination of connected primary care clinics with telemedicine and artificial intelligence. The company currently has an ecosystem of over 100,000 active patients and has plans to rapidly increase that number both domestically and internationally.
Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI) has recently engaged discussions with Licensed Producers under the Access to Cannabis for Medical Purposes Regulation, other licensed medical cannabis companies and government officials in order to establish a framework for both patient and physician education. Furthermore, the Company is actively recruiting additional physicians for its existing clinics and a cannabis focused physician that is licensed in Canada.
This move could prove to be and exciting one for Premier. The Canadian medical cannabis clinic market is estimated to be worth approximately $2.35 billion by 2025. With this in mind, the company said that it expects to provide additional updates on acquisitions in Q4-18 and Q1-19.
This news comes as Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI) begins rolling out new initiatives. Earlier in November, the company announce that as a part of its expansion plans it will enter the Pharmacy market via acquisition and/or launching a new Canada based pharmacy in H1-2019.
Karyopharm Therapeutics Inc. (KPTI) saw its share price jump during pre market trading on Monday. The clinical-stage pharmaceutical company recently reported positive top-line results from the Phase 2b SADAL (Selinexor Against Diffuse Aggressive Lymphoma) study evaluating selinexor, the Company's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior multi-agent therapies and who are ineligible for transplantation, including high dose chemotherapy with stem cell rescue.
Selinexor recently received Fast Track designation from the FDA for the patient population evaluated in the SADAL study. Karyopharm plans to submit a New Drug Application (NDA) to the FDA during the first half of 2019, with a request for accelerated approval for oral single-agent selinexor as a new treatment for patients with relapsed or refractory DLBCL.
Sharon Shacham, PhD, MBA, President and Chief Scientific Officer of Karyopharm, said, "In addition to the compelling efficacy and safety data observed with single agent oral selinexor, we were especially pleased to see strong response rates in patients with both the GCB and non-GCB subtypes."
CASI Pharmaceuticals, Inc. (CASI) is a U.S.-based biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients in China, U.S., and throughout the world.
This morning, CASI announced that it has received National Medical Products Administration ("NMPA") (formerly, the China FDA) approval of Melphalan Hydrochloride For Injection (EVOMELA®), for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma. In addition, CASI was also granted approval of EVOMELA® for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.
CASI Pharmaceuticals Executive Chairman Wei-Wu He, Ph.D., commented, "NMPA approval of Melphalan Hydrochloride For Injection (EVOMELA®) is encouraging news for patients in China with multiple myeloma as there is no commercially available melphalan formulation in the country. EVOMELA's approval therefore addresses a significant unmet medical need."
Teladoc (TDOC) provides virtual care options for clients and patients. Last month, the company announced the launch of Best Doctors Specialty Pharmacy Services, the first virtual care solution designed to tackle rising prescription drug costs using advanced analytics and an expert medical opinion. This unique analytics-driven virtual care solution helps employers and plan sponsors identify members with complex conditions such as Crohn's disease, psoriasis, lupus, or rheumatoid arthritis, and then engages an expert clinical team to carefully review the diagnosis and treatment plan to ensure the right course of action for each patient.
The service is initiated through a data-driven process that proactively and anonymously identifies those within a population who are most likely to benefit from an expert review of their diagnoses, treatment plans, and prescriptions. Best Doctors clinical experts can view an entire population, evaluate a high-risk group, or even identify an individual who would benefit from an in-depth case review.
"We already know that Best Doctors services have life changing results for our plan members - over half that access Best Doctors end up seeing a change in diagnosis or treatment," said Brad Fedorchuk, Senior Vice-President, Group Customer Experience & Marketing, Great-West Life. "What makes this program so exciting is that we can now leverage the power of our claims data and data analytics to proactively bring these life changing services to our members that need them most, and at the same time, help our plan sponsors lower the cost of their benefit programs."
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid "500,000" shares of restricted common shares. We were paid an additional $100,000 (CASH) for continued coverage. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six month restriction is complete on 4/1/2019 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.